Heart failure is a frequent and often fatal complication of diabetes. The 2018 Clinical Practice Guidelines mark a major shift in treatment, prioritizing agents that specifically reduce heart failure hospitalizations and identifying those that may cause harm. These flashcards are designed to help pharmacists and healthcare professionals memorize the safety profiles and outcome data for SGLT2 inhibitors, TZDs, and DPP-4 inhibitors in this high-risk population.
Key Topics Covered:
Therapeutic Benefit: Identifying the specific role of SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) in reducing the risk of heart failure hospitalization in patients with established cardiovascular disease.
Agents to Avoid: Recognizing the risk of fluid retention and heart failure exacerbation associated with Thiazolidinediones (TZDs).
Safety Signals: Recalling the specific concern regarding saxagliptin and increased heart failure hospitalization rates seen in the SAVOR-TIMI 53 trial.
Epidemiology: Understanding that diabetes is an independent risk factor for heart failure (“diabetic cardiomyopathy”) and significantly worsens prognosis.
Neutral Agents: Knowing which drug classes (e.g., most GLP-1 receptor agonists) are considered safe/neutral regarding heart failure outcomes .